Skip to main content

Table 3 Summary of adverse events experienced by patients in the HOPEFUL-3 study (n = 172)a

From: Low disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study

 

ADA continuation group (n = 79)

ADA discontinuation group (n = 93)

p Valueb

Any adverse event

26 (32.9)

9 (9.7)

<0.001

Serious adverse event

3 (3.8)

1 (1.1)

0.33

Infectious adverse event

9 (11.4)

4 (4.3)

0.09

Serious infection

1 (1.3)

0 (0.0)

NA

Bronchiolitis

1 (1.3)

0 (0.0)

NA

  1. ADA Adalimumab, NA Not applicable
  2. aValues are expressed as n (%)
  3. bStatistical significance as assessed by Fisher’s exact test
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us